Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
作者信息
Amengual Jennifer E, Raphael Bruce G
出版信息
Leuk Lymphoma. 2010 Jul;51(7):1347-50. doi: 10.3109/10428194.2010.486091.
PMID:20572801
Abstract
摘要
相似文献
1
Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
Leuk Lymphoma. 2010 Jul;51(7):1347-50. doi: 10.3109/10428194.2010.486091.
2
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Leuk Lymphoma. 2010 Sep;51(9):1583-4. doi: 10.3109/10428194.2010.508190.
3
Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
Nat Clin Pract Oncol. 2006 Mar;3(3):165-8; quiz 169. doi: 10.1038/ncponc0430.
4
Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
Leuk Res. 2010 Aug;34(8):e197-9. doi: 10.1016/j.leukres.2010.01.019. Epub 2010 Mar 7.
5
Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
Ann Oncol. 2009 Feb;20(2):390-2. doi: 10.1093/annonc/mdn726.
6
Alemtuzumab in lymphoproliferate disorders.
Rev Clin Exp Hematol. 2002 Dec;6(4):435-48; discussion 449-50. doi: 10.1046/j.1468-0734.2002.00308.x.
7
Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma.
N Engl J Med. 2006 Jun 8;354(23):2514-5. doi: 10.1056/NEJMc053129.
8
Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.
Leuk Lymphoma. 2011 Feb;52(2):317-20. doi: 10.3109/10428194.2010.529203. Epub 2010 Nov 11.
9
The role of alemtuzumab in the management of T-cell malignancies.
Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52. doi: 10.1053/j.seminoncol.2006.01.029.
10
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x. Epub 2007 Dec 21.
引用本文的文献
1
Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Leuk Lymphoma. 2024 Jun;65(6):736-745. doi: 10.1080/10428194.2024.2329996. Epub 2024 Mar 22.
2
An update on the management of peripheral T-cell lymphoma and emerging treatment options.
J Blood Med. 2011;2:119-29. doi: 10.2147/JBM.S8627. Epub 2011 Sep 12.
Zotero 插件